Innovent Biologics

Diversified biologics

1801 · HKEX · China

Public Market Listing

1801HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Innovent Biologics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(18 total)
18Total Assets
4Approved
9Phase 3 / Filed
5Phase 1–2 / Early
14Diseases
Quick filter:
Showing 18 of 18 assets
Target & Modality
Pemigatinib(Pemazyre)
Approved
FGFR1/2/3Small molecule
Non-Small Cell Lung CancerBiliary Tract Cancer
Cholangiocarcinoma
Approved
FLT3Small molecule
Acute Myeloid Leukemia
Selpercatinib(Retevmo)
Approved
RETSmall molecule
Non-Small Cell Lung CancerSolid Tumors
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer
Phase 3
GPRC5D x BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 3
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 3
PD-1 x IL-2Rα (IL2RA)Multispecific antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 3
EGFR · EGFR T790M (resistant mutant, selective over wild-type EGFR)Small molecule
Non-Small Cell Lung Cancer
Phase 3
GLP-1/glucagon receptor (dual)Peptide
ObesityType 2 Diabetes
Phase 3
BCR-ABL (also AKT, c-Kit, ERK)Small molecule
Acute Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemia with T315I Mutation
Phase 3
IL-23 p19Monoclonal antibody
Inflammatory Bowel DiseasePsoriasis
Ulcerative Colitis
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Tafolecimab(Sintbilo)
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Fulzerasib(Dupert)
Phase 2
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 2
Angiotensinogen (AGT)RNA / oligonucleotide
Hypertension

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
IBI363Phase 2Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Est. primary completion 2026-11-30 · NCT07122687 · CT.gov ↗
What to watch
December 2026 (4)
IBI363Phase 2Melanoma
Est. primary completion 2026-12-31 · NCT06797297 · CT.gov ↗
What to watch
IBI363Phase 2Resectable Stage II-III Non-small Cell Lung Cancer
Est. primary completion 2026-12-31 · NCT07402070 · CT.gov ↗
What to watch
IBI3003Phase 2Multiple Myeloma
Est. primary completion 2026-12-31 · NCT07764861 · CT.gov ↗
What to watch
mazdutidePhase 3Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Est. primary completion 2026-12-31 · NCT06884293 · CT.gov ↗
What to watch
2027 (11)
March 2027 (1)
OlverembatinibPhase 3GIST
Est. primary completion 2027-03-31 · NCT06640361 · CT.gov ↗
What to watch
May 2027 (2)
QuizartinibPhase 1/2Acute Myeloid Leukemia
Est. primary completion 2027-05-01 · NCT03793478 · CT.gov ↗
What to watch
mazdutidePhase 3Sleep Apnea, Obstructive, Obesity
Est. primary completion 2027-05-07 · NCT06931028 · CT.gov ↗
What to watch
June 2027 (2)
Sintilimab + LimertinibPhase 1/2Solid Tumor
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
OlverembatinibPhase 3Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Est. primary completion 2027-06-30 · NCT06423911 · CT.gov ↗
What to watch
September 2027 (2)
mazdutidePhase 2Obesity, Overweight
Est. primary completion 2027-09 · NCT06143956 · CT.gov ↗
What to watch
PegenzileukinPhase 1/2Plasma Cell Myeloma Refractory
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
October 2027 (2)
mazdutidePhase 3Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Est. primary completion 2027-10-31 · NCT07255209 · CT.gov ↗
What to watch
LimertinibPhase 3Locally Advanced or Metastatic NSCLC
Est. primary completion 2027-10-31 · NCT07109531 · CT.gov ↗
What to watch
December 2027 (2)
SintilimabPhase 2/3Hepatocellular Carcinoma (HCC)
Est. primary completion 2027-12-31 · NCT07490262 · CT.gov ↗
What to watch
OlverembatinibPhase 3Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Est. primary completion 2027-12-31 · NCT06051409 · CT.gov ↗
What to watch
2028 (5)
June 2028 (1)
QuizartinibPhase 2Acute Myeloid Leukemia, Leukemia
Est. primary completion 2028-06-06 · NCT06824168 · CT.gov ↗
What to watch
September 2028 (1)
OlverembatinibPhase 1/2Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Est. primary completion 2028-09 · NCT04501120 · CT.gov ↗
What to watch
October 2028 (2)
IBI363Phase 2Melanoma
Est. primary completion 2028-10-19 · NCT06081920 · CT.gov ↗
What to watch
IBI363Phase 3Colorectal Cancer
Est. primary completion 2028-10-31 · NCT07722494 · CT.gov ↗
What to watch
November 2028 (1)
IBI363Phase 3IO Resistant Squamous and Nonsquamous NSCLC
Est. primary completion 2028-11-01 · NCT07217301 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
TaletrectinibPhase 3Non Small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06564324 · CT.gov ↗
What to watch
March 2029 (1)
IBI3016Phase 2Hypertension
Est. primary completion 2029-03-27 · NCT07352969 · CT.gov ↗
What to watch
May 2029 (1)
IBI3003Phase 3Relapsed or Refractory Multiple Myeloma
Est. primary completion 2029-05-31 · NCT07623798 · CT.gov ↗
What to watch
December 2029 (1)
picankibartPhase 2/3Psoriatic Arthritis
Est. primary completion 2029-12-31 · NCT07295509 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
SintilimabPhase 3Locally Advanced Rectal Cancer
Est. primary completion 2030-03-25 · NCT07917468 · CT.gov ↗
What to watch
June 2030 (2)
QuizartinibPhase 3Leukemia
Est. primary completion 2030-06-26 · NCT06578247 · CT.gov ↗
What to watch
SintilimabPhase 2CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-06-30 · NCT07483567 · CT.gov ↗
What to watch
August 2030 (1)
TaletrectinibPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-08-30 · NCT07154706 · CT.gov ↗
What to watch
December 2030 (1)
LimertinibPhase 3EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
Est. primary completion 2030-12-30 · NCT07897188 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Pemigatinib · PemazyrePhase 2Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
Est. primary completion 2031-02-25 · NCT07862998 · CT.gov ↗
What to watch
December 2031 (1)
SintilimabPhase 2/3Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2031-12-31 · NCT07643623 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(14)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

4 January 2027FDA action dateTaletrectinibFDA target action date for IBTROZI sNDA
US, FDA · Source ↗

Recent

9 November 2026Topline resultTafolecimabCREDIT-5 Phase 3 meets its primary endpoint
Innovent Biologics · Source ↗
16 September 2026ApprovalTaletrectinibFDA approves IBTROZI supplemental application with updated duration of response
US, FDA · Nuvation Bio Inc. · Source ↗
29 June 2026Filing acceptedTaletrectinibUK MHRA validates taletrectinib MAA
UK, MHRA · Source ↗
June 2026Filing acceptedTaletrectinibMHRA validates taletrectinib marketing authorisation application
UK, MHRA · Nuvation Bio Inc. and Eisai · Source ↗
6 May 2026Filing acceptedTaletrectinibFDA accepts sNDA for IBTROZI with updated duration of response data
US, FDA · Source ↗
March 2026Filing acceptedTaletrectinibEMA validates taletrectinib marketing authorisation application
EU, EMA · Nuvation Bio Inc. and Eisai · Source ↗
25 November 2025Filing acceptedmazdutideNMPA CDE accepts the mazdutide 9 mg supplementary application for review
CN, NMPA · Innovent Biologics · Source ↗
19 November 2025Topline resultmazdutideGLORY-2 (NCT06164873) Phase 3 of mazdutide 9 mg met its primary and all key secondary endpoints
Innovent Biologics · Source ↗
26 October 2025Topline resultmazdutideDREAMS-3 (NCT06184568) Phase 3 head-to-head versus semaglutide met its primary endpoint
Innovent Biologics, Inc. · Source ↗
27 June 2025ApprovalmazdutideNMPA approves mazdutide for chronic weight management
CN, NMPA · Source ↗
5 June 2025Filing acceptedSintilimabNMPA accepts the NDA for sintilimab plus fruquintinib in renal cell carcinoma
CN, NMPA · HUTCHMED and Innovent Biologics · Source ↗
19 March 2025Topline resultSintilimabFRUSICA-2 Phase II/III of fruquintinib plus sintilimab meets primary endpoint

The 12 most recent of 13 past events are shown.

Financial reports

Quarterly & interim (5)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$821M$139M$1.5B—report ↗

Innovent Biologics reported revenue of $821.43M, up 49.5% YoY, R&D spend of $139.2M, down 28.4% YoY, and cash and equivalents of $1,536.05M for H1 2025.

Figures only: this period's report disclosed no narrative text

View 4 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$549M$195M$1.1B$55Mreport ↗
2023-H1$390M$133M$1.1B$20Mreport ↗
2022-H1$346M$181M$1.2B$147Mreport ↗
2021-H1$300M$161M$1.7B$182Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.9B$387M$2.6B—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.3B$373M$1.4B$13Mreport ↗
2023-FY$878M$315M$1.5B$145Mreport ↗
2022-FY$678M$428M$1.3B$325Mreport ↗
2021-FY$662M$384M$1.4B$487Mreport ↗